Cyxone AB is a clinical stage biotechnology company, which engages in the development of immunomodulation drugs for the treatment of autoimmune diseases. Its product portfolio include T20K for multiple sclerosis in a preclinical program; and Rabeximod for rheumatoid arthritis and Covid-19. The company was founded by Bert Roland Kari Junno in July 13, 2015 and is headquartered in Malmo, Sweden.